Zhong Ji Longevity Science Group Limited announced a further delay in sending its shareholder circular for the proposed acquisition of a 25% equity interest in Asian Integrated Cell Laboratory Limited, a transaction classified as both major and connected and involving the issuance of convertible notes under a specific mandate.

Originally scheduled for dispatch on or before 30 April 2026, the circular is now expected to be delivered on or before 29 May 2026. The Board attributed the postponement to the need for additional time to “prepare and finalise certain information” required in the document, which will include: 1. Detailed information on the target company and the Sale and Purchase Agreement. 2. Recommendations from the Independent Board Committee. 3. An independent financial adviser’s opinion for minority shareholders. 4. Financial data of the target company and other disclosures mandated by the Hong Kong Listing Rules. 5. Notice of the forthcoming special general meeting (SGM).

No changes to the terms of the acquisition or the convertible notes were disclosed in the latest update. The Board, led by Chairman and CEO Yan Li, reiterated its commitment to completing the documentation within the revised timeline.

The company has issued five prior announcements on this transaction and its related circular delays (dated 22 December 2025; 16 January 2026; 9 March 2026; 8 April 2026; and 30 April 2026).

Board composition at the time of this announcement remains: • Executive Directors: Yan Li (Chairman), Li Xiaoshuang • Non-executive Directors: Dr. He Yiwu, Lyn Changsheng • Independent Non-executive Directors: Huang Jiang, Prof. Huang Cibo, Wang Huijuan, Tam Mei Chu

The company reiterated that, in case of any discrepancy, the English version of the announcement prevails over the Chinese version.